Brief: Agios Provides Update On Phase 2 Trial Of Tebapivat In Sickle Cell Disease

Agios Pharmaceuticals

21/07/2026 12:26

July 21 (Reuters) - Agios Pharmaceuticals Inc AGIO.O:
AGIOS PROVIDES UPDATE ON PHASE 2 TRIAL OF TEBAPIVAT IN SICKLE CELL DISEASE
AGIOS PHARMACEUTICALS - WILL NOT ADVANCE TEBAPIVAT IN SICKLE CELL DISEASE
AGIOS PHARMACEUTICALS - PRIMARY ENDPOINT ACHIEVED BY UP TO 47.1% IN TEBAPIVAT ARMS; 33.3% IN PLACEBO ARM
AGIOS PHARMACEUTICALS - TEBAPIVAT SAFETY CONSISTENT WITH PRIOR SICKLE CELL DISEASE TRIALS
AGIOS PHARMACEUTICALS - FDA PRIORITY REVIEW FOR MITAPIVAT IN SICKLE CELL DISEASE; PDUFA DATE NOVEMBER 1, 2026
Source text: ID:nGNXbgGfWJ
Further company coverage: AGIO.O

 ((Reuters.Briefs@thomsonreuters.com;))